SNY Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 36.7% compared to Sanofi's net margin of -1.89%. Sanofi's return on equity of 12.45% beat BioNTech SE's return on equity of -3.01%.

Sanofi has a consensus price target of $58.08, signalling upside risk potential of 22.31%. On the other hand BioNTech SE has an analysts' consensus of $140.90 which suggests that it could grow by 18.07%. Given that Sanofi has higher upside potential than BioNTech SE, analysts believe Sanofi is more attractive than BioNTech SE.

Sanofi has a beta of 0.460, which suggesting that the stock is 53.969% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.393, suggesting its more volatile than the S&P 500 by 39.311%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.62%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than BioNTech SE quarterly revenues of $1.8B. Sanofi's net income of $4.5B is higher than BioNTech SE's net income of -$33.5M. Notably, Sanofi's price-to-earnings ratio is 12.17x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.73x versus 8.12x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 36.7% compared to Sanofi's net margin of -19.69%. Sanofi's return on equity of 12.45% beat Moderna, Inc.'s return on equity of -30.18%.

Sanofi has a consensus price target of $58.08, signalling upside risk potential of 22.31%. On the other hand Moderna, Inc. has an analysts' consensus of $37.70 which suggests that it could fall by -17.05%. Given that Sanofi has higher upside potential than Moderna, Inc., analysts believe Sanofi is more attractive than Moderna, Inc..

Sanofi has a beta of 0.460, which suggesting that the stock is 53.969% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.62%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Moderna, Inc. quarterly revenues of $1B. Sanofi's net income of $4.5B is higher than Moderna, Inc.'s net income of -$200M. Notably, Sanofi's price-to-earnings ratio is 12.17x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.73x versus 7.89x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of 36.7% compared to Sanofi's net margin of -287.29%. Sanofi's return on equity of 12.45% beat Novavax, Inc.'s return on equity of --.

Sanofi has a consensus price target of $58.08, signalling upside risk potential of 22.31%. On the other hand Novavax, Inc. has an analysts' consensus of $12.89 which suggests that it could grow by 31.25%. Given that Novavax, Inc. has higher upside potential than Sanofi, analysts believe Novavax, Inc. is more attractive than Sanofi.

Sanofi has a beta of 0.460, which suggesting that the stock is 53.969% less volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.367, suggesting its more volatile than the S&P 500 by 136.738%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.62%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi pays 66.53% of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Novavax, Inc. quarterly revenues of $70.4M. Sanofi's net income of $4.5B is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Sanofi's price-to-earnings ratio is 12.17x while Novavax, Inc.'s PE ratio is 5.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.73x versus 1.56x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 36.7% compared to Sanofi's net margin of 38.89%. Sanofi's return on equity of 12.45% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Sanofi has a consensus price target of $58.08, signalling upside risk potential of 22.31%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $831.38 which suggests that it could grow by 7.8%. Given that Sanofi has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Sanofi is more attractive than Regeneron Pharmaceuticals, Inc..

Sanofi has a beta of 0.460, which suggesting that the stock is 53.969% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Sanofi has a quarterly dividend of $2.20 per share corresponding to a yield of 4.62%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.88 per share. Sanofi pays 66.53% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi quarterly revenues are $12.2B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Sanofi's net income of $4.5B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Sanofi's price-to-earnings ratio is 12.17x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi is 2.73x versus 5.97x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.